ASS234 is a multitarget directed propargylamine for alzheimer's disease therapy. References: Serrano MP, Herrero-Labrador R, Futch HS, Serrano J, Romero A, Fernandez AP, Samadi A, Unzeta M, Marco-Contelles J, Martínez-Murillo R. The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease. J Psychiatry Neurosci. 2016 Sep 20;41(6):150209. doi: 10.1503/jpn.150209. [Epub ahead of print] PubMed PMID: 27636528.

纯度：≥98%

CAS：1334106-34-1